Jove
Visualize
お問い合わせ

関連する概念動画

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

15
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

45
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
45

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Effects of Protein and Amino Acid Supplementation on Physical Performance in Patients With Chronic Heart Failure - A Systematic Review and Meta-Analysis.

Circulation reports·2026
Same author

Long-term Safety and Efficacy of Bempedoic Acid in Japanese Patients with Hypercholesterolemia: the CLEAR-J LONG.

Journal of atherosclerosis and thrombosis·2025
Same author

Three-Year Outcome of Drug Coated Balloon Angioplasty Following Atherectomy for Severely Calcified Coronary Lesions.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2025
Same author

Successful Treatment of Infective Endocarditis at 33 Weeks' Gestation Causing Acute Left Heart Failure.

Clinical case reports·2025
Same author

A male patient with pseudoxanthoma elasticum caused by isodisomy of chromosome 16 containing a nonsense variant of the <i>ABCC6</i> gene: A quarter-century treatment experience.

Atherosclerosis plus·2025
Same author

Circulating type IV collagen 7S concentrations are associated with left atrial remodeling indices in patients with atrial fibrillation.

The Journal of international medical research·2025
Same journal

Optimization of Infectious Disease Treatment via Clinical Practice-Based Personalized Therapy and Big Data Analysis.

Biological & pharmaceutical bulletin·2026
Same journal

Development of Nucleic Acid-Loaded Nanobubbles for Ultrasound-Mediated Therapeutic Applications.

Biological & pharmaceutical bulletin·2026
Same journal

An Improved Brain-Penetrating Nanoformulation of the VIPR2 Antagonist Peptide KS-133 for Treating Cognitive Impairment in Schizophrenia.

Biological & pharmaceutical bulletin·2026
Same journal

A Quantitative in Vitro Framework Reveals State-Dependent Pharmacological Responses to Repeated Inflammatory Stimulation in Synovial Fibroblasts.

Biological & pharmaceutical bulletin·2026
Same journal

Pinolenic Acid Inhibits Prostanoid TP Receptor-Mediated Contraction in Porcine Coronary Arteries.

Biological & pharmaceutical bulletin·2026
Same journal

Lipopolysaccharide-Induced Changes in Facial Expression and Orofacial Movement in Mice.

Biological & pharmaceutical bulletin·2026
関連記事をすべて見る
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する実験動画

Updated: Sep 9, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.8K

トラストズマブの心臓毒性:メカニズムと管理

Minoru Wakasa1, Miharu Masaki1, Kouji Kajinami1

  • 1Department of Cardiology, Kanazawa Medical University.

Biological & pharmaceutical bulletin
|August 31, 2025
PubMed
まとめ
この要約は機械生成です。

トラストズマブは乳がんの重要な薬ですが 心臓の問題を引き起こします 心臓の危険性や 診断方法や 治療法を理解することは 患者の安全にとって 極めて重要です

キーワード:
心臓毒性ヒトの表皮成長因子受容体2型トラストズマブ

さらに関連する動画

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.9K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K

関連する実験動画

Last Updated: Sep 9, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.8K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.9K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K

科学分野:

  • 腫瘍学
  • 心臓病科
  • 薬理学について

背景:

  • トラストズマブは,広く使用されている乳がん治療法です.
  • 心律不全,心筋不全,心不全などの心臓毒性の危険性があります.
  • トラストズマブ誘発の心臓毒性のメカニズムは解明されており,潜在的に赤血球腫瘍遺伝子B2受容体が関与している.

研究 の 目的:

  • 抗ヒト表皮成長因子受容体2療法に関連した心臓毒性のメカニズム,診断方法,治療/予防戦略をレビューする.
  • トラストズマブの心的副作用の管理に関する包括的な概要を提示する.

主な方法:

  • トラストズマブの心臓毒性に関する既存の文献のレビュー.
  • エコーカルディオグラフィー,心臓バイオマーカー (トロポニンI,NT-プロBNP),MRIなどの診断ツールの検討
  • 現在と新興の薬理学的介入の分析

主要な成果:

  • トラストズマブ療法における心臓毒性は重大な懸念事項である.
  • 早期診断は心臓機能評価とバイオマーカーによって可能である.
  • 確立された心不全治療法 (例えばベータブロッカー,ACE阻害剤) と新しい薬 (例えばRNAI,SGLT2阻害剤) は有望である.
  • PCSK9阻害剤は心臓保護効果についても研究されています.

結論:

  • トラストズマブの心臓毒性の効果的な管理には,多面的なアプローチが必要です.
  • 心臓の機能を監視し,適切な診断ツールを使用することが不可欠です.
  • 既存の治療法と新しい治療法を含む薬理学的介入は,心臓の有害事象の予防と治療の鍵です.